Post completion, the Transaction is expected to have an additional positive capital impact of c.65 basis points1 on the Group’s CET1 ratio, upon the full payment of the deferred consideration and without taking into consideration any positive impact from the earnout, thus making the Transaction overall capital accretive.Īfter the success of 2022’s educational programs, Wargaming Forge is ready to announce the first courses to be launched this year involving our offices in Cyprus, Lithuania, Serbia and the Czech Republic. Overall, including the release of risk weighted assets, the impact of the Transaction on the Group’s CET1 ratio since the agreements were signed in August 2020 for Portfolio A and January 2021 for Portfolio B is c.-50 basis points1. The completion of the Transaction increases the Group’s CET1 ratio as at 31 March 2021 of 14.4% to 14.6% (pro forma). The consideration can be increased through an earnout arrangement, depending on the performance of each of the Portfolios. The net consideration reflects adjustments resulting from, inter alia, loan repayments received on the Portfolios since the reference date of 30 September 2019. The remaining amount is payable in four instalments up to December 2025 without any conditions attached. The net consideration for the Transaction amounts to c.€560 mn, of which c.€165 mn have been received in cash by completion. Project Helix 2 (the “Transaction”) refers to the sale of portfolios of loans with a total gross book value of €1,339 mn1 (of which €1,311 mn1 relate to non-performing exposures) (“Portfolios A and B”), secured over real estate collateral, to funds affiliated with Pacific Investment Management Company LLC (“PIMCO”), the agreements for which were announced on 3 August 2020 and on 18 January 2021. Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47.Bank of Cyprus Holdings Public Limited Company (“BOC Holdings” and, together with its subsidiaries, the “Group”) is pleased to announce the completion of Project Helix 2 (Portfolios A and B).
#Helix loans registration#
The securities offered have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, US persons absent registration or an applicable exemption from registration requirements. In connection with the closing, the company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The common shares issued under the private placement are subject to a statutory hold period of four months and one day ending on March 4, 2023, in accordance with applicable securities law. READ: Helix BioPharma advances clinical development of lead candidate L-DOS47, but manages to decrease R&D expenses We look forward to continued efforts toward this exciting program” said Artur Gabor, CEO of Helix in a statement. “We would like to thank all investors for their strong support and confidence in Helix. The company said it intends to use the net proceeds of the private placement for working capital and advancing its L-DOS47 drug development program. (TSX:HBP) said it has closed a private placement financing for net proceeds of C$4,629,019.86 from the issuance of 25,716,777 common shares at a price of $0.18 each.
0 kommentar(er)
